ReviewJugan geon-gang gwa jilbyeong2025
[Research and International Cooperation for Shortening the Treatment Duration of Tuberculosis].
Review in Jugan geon-gang gwa jilbyeong, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- [Notification Status and Characteristics of Foreign Tuberculosis Cases in the Gyeongnam Region during 2017-2023].Jugan geon-gang gwa jilbyeong · 2025Article
- [Commemoration of the Special Issue on Tuberculosis in "Jugan geon-gang gwa jilbyeong · 2025Article
- [Commemorating the 15th Tuberculosis Prevention Day: Challenges and Achievements of Republic of Korea's Tuberculosis Control Policies].Jugan geon-gang gwa jilbyeong · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This study aimed to explore advancements in tuberculosis (TB) diagnosis and treatment technologies, assess recent research trends in reducing treatment duration, and emphasize the importance of international collaborative research. Methods: A comprehensive review of global TB reports, epidemiological studies, and clinical research findings was conducted, with a particular focus on novel non-sputum-based diagnostic methods, therapeutic targets, innovative treatment strategies, and global collaborative efforts. Results: Extensive research continues to advance TB diagnosis, treatment, and support. Progress in molecular diagnostic technologies has substantially contributed to early detection, leading to rapid improvements in treatment approaches. Technological advancements aimed at shortening treatment duration are expected to play a crucial role in the eradication of TB. Additionally, international research collaborations have been established to accelerate progress in this field, with the Republic of Korea also actively contributing to these efforts. Conclusions: Targeted investments in research focused on reducing treatment duration, and the resulting advancements are anticipated to be essential in achieving the goal of TB eradication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.